Cirtuvivint is under clinical development by Biosplice Therapeutics and currently in Phase I for Refractory Acute Myeloid Leukemia. According to GlobalData, Phase I drugs for Refractory Acute Myeloid ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback